CAPR Similar Chart Price Prediction
The price of CAPR is predicted to go up 1.57%, based on the high correlation periods with SPTN. The similarity of these two price pattern on the periods is 91.54%.
CAPR
SPTN
Up: 1.57%Similarity: 91.54%
CAPR Revenue Forecast
CAPR EPS Forecast
CAPR FAQs
What is CAPR revenue forecast for next quarter？
CAPR Analyst's Forecast
Catherine Novack
Jones Trading
Strong Buy
2024-11-18
Price Target
$40
Upside
+117.63%
JonesResearch initiated coverage of Capricor Therapeutics with a Buy rating and $40 price target. Capricor's lead asset is deramiocel, a mutation-agnostic cell therapy for Duchenne muscular dystrophy cardiomyopathy, the analyst tells investors in a research note. The firm likes deramiocel, saying Cardiomyopathy is now the leading cause of death in DMD and there are no approved therapies for this indication. Cardiologist feedback indicates high level of excitement for deramiocel, contends the firm.
Kristen Kluska
Cantor Fitzgerald
Buy
2024-11-14
Price Target
$25 → $30
Upside
+62.95%
Edward Tenthoff
Piper Sandler
Buy
2024-10-21
Price Target
$35
Upside
+60.7%
